Type
1.
Taleo F, Taleo G, Graves P, Wood P College of Public Health, Medical and Veterinary Sciences, Division of Tropical Health and Medicine, James Cook University, Kim SH, Ozaki M, et al. Surveillance efforts after mass drug administration to validate elimination of lymphatic filariasis as a public health problem in Vanuatu. Tropical medicine and health [Internet]. 2017;45:18. Available from: http://tinyurl.com/y8gtwjwn
Type
1.
Biradar M, Holyachi S. Coverage and compliance of mass drug administration against lymphatic filariasis in Kalaburgi district. International journal of community medicine and public health [Internet]. 2017;4(7):2502-5. Available from: http://www.ijcmph.com/index.php/ijcmph/article/view/1458/1271
Type
1.
Nana-Djeunga H, Tchouakui M, Njitchouang G, Tchatchueng-Mbougua J, Nwane P, Domche A, et al. First evidence of lymphatic filariasis transmission interruption in Cameroon: Progress towards elimination. PLoS neglected tropical diseases [Internet]. 2017;11(6):e0005633. Available from: http://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0005633&type=printable
Type
1.
Mwingira U National Institute for Medical Research (NIMR), Chikawe M, Mandara WL, Mableson H, Uisso C, Mremi I, et al. Lymphatic filariasis patient identification in a large urban area of Tanzania: An application of a community-led Mhealth system. PLoS neglected tropical diseases [Internet]. 2017;11(7):e0005748. Available from: http://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0005748&type=printable
Type
1.
Barda B, Albonico M, Buonfrate D, Ame S, Ali S, Speich B, et al. Side benefits of mass drug administration for lymphatic filariasis on Strongyloides stercoralis prevalence on Pemba Island, Tanzania. The American journal of tropical medicine and hygiene. 2017;
Type
1.
Dickson B, Graves P, McBride W. Lymphatic filariasis in Mainland Southeast Asia: A systematic review and meta-analysis of prevalence and disease burden. Tropical medicine and infectious disease [Internet]. 2017;2(3). Available from: http://www.mdpi.com/2414-6366/2/3/32/pdf
Type
1.
Eigege A, Evans D, Noland G, Davies E Federal Ministry of Health, Umaru J, Adelamo S, et al. Criteria to stop mass drug administration for Lymphatic filariasis have been achieved throughout Plateau and Nasarawa States, Nigeria. The American journal of tropical medicine and hygiene. 2017;
Type
1.
Martindale, MacKenzie, Mkwanda, Smith, Stanton, Molyneux, et al. “Unseen” Caregivers: The disproportionate gender balance and role of females in the home-based care of lymphatic filariasis patients in Malawi. Frontiers in women’s health [Internet]. 2017;2(2):1-3. Available from: https://oatext.com/pdf/FWH-2-126.pdf
Type
1.
Coutts S, King J, Pa’au M, Fuimaono S, Roth J, King MR, et al. Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration. Tropical medicine and health [Internet]. 2017;45:22. Available from: http://tinyurl.com/ydx66ge8
Type
1.
Mengistu B, Deribe K, Kebede F, Martindale S, Hassan M, Sime H, et al. The national programme to eliminate Lymphatic filariasis from Ethiopia. Ethiopian medical journal [Internet]. 2017;55(4):45-54. Available from: http://www.emaemj.org/index.php/EMJ/article/download/646/pdf_120
Pagination
- Previous page
- Page 15
- Next page